568 related articles for article (PubMed ID: 26970174)
21. Randomized Comparison of Pazopanib and Doxorubicin as First-Line Treatment in Patients With Metastatic Soft Tissue Sarcoma Age 60 Years or Older: Results of a German Intergroup Study.
Grünwald V; Karch A; Schuler M; Schöffski P; Kopp HG; Bauer S; Kasper B; Lindner LH; Chemnitz JM; Crysandt M; Stein A; Steffen B; Richter S; Egerer G; Ivanyi P; Zimmermann S; Liu X; Kunitz A
J Clin Oncol; 2020 Oct; 38(30):3555-3564. PubMed ID: 32840417
[TBL] [Abstract][Full Text] [Related]
22. Phase II trial of pazopanib (GW786034), an oral multi-targeted angiogenesis inhibitor, for adults with recurrent glioblastoma (North American Brain Tumor Consortium Study 06-02).
Iwamoto FM; Lamborn KR; Robins HI; Mehta MP; Chang SM; Butowski NA; Deangelis LM; Abrey LE; Zhang WT; Prados MD; Fine HA
Neuro Oncol; 2010 Aug; 12(8):855-61. PubMed ID: 20200024
[TBL] [Abstract][Full Text] [Related]
23. A remarkable response to pazopanib, despite recurrent liver toxicity, in a patient with a high grade endometrial stromal sarcoma, a case report.
Verschoor AJ; Warmerdam FARM; Bosse T; Bovée JVMG; Gelderblom H
BMC Cancer; 2018 Jan; 18(1):92. PubMed ID: 29357824
[TBL] [Abstract][Full Text] [Related]
24. Differences in the responses to pazopanib and the prognoses of soft tissue sarcomas by their histological eligibility for the PALETTE study.
Nakano K; Motoi N; Inagaki L; Tomomatsu J; Gokita T; Ae K; Tanizawa T; Shimoji T; Matsumoto S; Takahashi S
Jpn J Clin Oncol; 2015 May; 45(5):449-55. PubMed ID: 25724217
[TBL] [Abstract][Full Text] [Related]
25. Pazopanib and soft-tissue sarcomas. Too toxic.
Prescrire Int; 2013 Jun; 22(139):145-7. PubMed ID: 23866345
[TBL] [Abstract][Full Text] [Related]
26. Pazopanib: in advanced soft tissue sarcoma.
Deeks ED
Drugs; 2012 Nov; 72(16):2129-40. PubMed ID: 23072642
[TBL] [Abstract][Full Text] [Related]
27. Real-world outcomes of pazopanib in metastatic soft tissue sarcoma: a retrospective Turkish oncology group (TOG) study.
Bilici A; Koca S; Karaagac M; Aydin SG; Eraslan E; Kaplan MA; Ocak B; Goksu SS; Paydas S; Akgul F; Derin S; Ergun Y; Yekeduz E; Erol C; Ozyukseler DT; Demiray AG; Karaca M; Guc ZG; Menekse S; Cinkir HY; Gumusay O; Sakin A; Ozkul O; Demir H; Erdem D; Besiroglu M; Unal OU; Acar R; Koral L; Sahin S; Sakalar T; Bahceci A; Ozveren A; Gunaydin UM; Seker MM; Sunar V; Dal P; Artac M; Turhal S
J Cancer Res Clin Oncol; 2023 Sep; 149(11):8243-8253. PubMed ID: 37067546
[TBL] [Abstract][Full Text] [Related]
28. An open-label extension study to evaluate safety and efficacy of pazopanib in patients with advanced renal cell carcinoma.
Sternberg CN; Davis ID; Deen KC; Sigal E; Hawkins RE
Oncology; 2014; 87(6):342-50. PubMed ID: 25227656
[TBL] [Abstract][Full Text] [Related]
29. Pazopanib does not bring remarkable improvement in patients with angiosarcoma.
Kitamura S; Yanagi T; Inamura Y; Hata H; Imafuku K; Yoshino K; Shimizu H
J Dermatol; 2017 Jan; 44(1):64-67. PubMed ID: 27569550
[TBL] [Abstract][Full Text] [Related]
30. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial.
van der Graaf WT; Blay JY; Chawla SP; Kim DW; Bui-Nguyen B; Casali PG; Schöffski P; Aglietta M; Staddon AP; Beppu Y; Le Cesne A; Gelderblom H; Judson IR; Araki N; Ouali M; Marreaud S; Hodge R; Dewji MR; Coens C; Demetri GD; Fletcher CD; Dei Tos AP; Hohenberger P; ;
Lancet; 2012 May; 379(9829):1879-86. PubMed ID: 22595799
[TBL] [Abstract][Full Text] [Related]
31. Balancing Prolonged Survival with QoL Using Low-dose Pazopanib Maintenance: A Comparison with the PALETTE Study.
Abe K; Yamamoto N; Hayashi K; Takeuchi A; Miwa S; Inatani H; Higuchi T; Taniguchi Y; Tsuchiya H
Anticancer Res; 2016 Jun; 36(6):2893-7. PubMed ID: 27272802
[TBL] [Abstract][Full Text] [Related]
32. Phase I pharmacokinetic and pharmacodynamic study of pazopanib in children with soft tissue sarcoma and other refractory solid tumors: a children's oncology group phase I consortium report.
Glade Bender JL; Lee A; Reid JM; Baruchel S; Roberts T; Voss SD; Wu B; Ahern CH; Ingle AM; Harris P; Weigel BJ; Blaney SM
J Clin Oncol; 2013 Aug; 31(24):3034-43. PubMed ID: 23857966
[TBL] [Abstract][Full Text] [Related]
33. Safety and Efficacy of Anlotinib, a Multikinase Angiogenesis Inhibitor, in Patients with Refractory Metastatic Soft-Tissue Sarcoma.
Chi Y; Fang Z; Hong X; Yao Y; Sun P; Wang G; Du F; Sun Y; Wu Q; Qu G; Wang S; Song J; Yu J; Lu Y; Zhu X; Niu X; He Z; Wang J; Yu H; Cai J
Clin Cancer Res; 2018 Nov; 24(21):5233-5238. PubMed ID: 29895706
[No Abstract] [Full Text] [Related]
34. Safety and efficacy of pazopanib as a second-line treatment and beyond for soft tissue sarcomas: A real-life tertiary-center experience in the MENA region.
Halim NA; Sayed RE; Alameh IA; Khoury J; Nakib CE; Zerdan MB; Charafeddine M; Farhat F; Karak FE; Assi HI
Cancer Treat Res Commun; 2021; 26():100275. PubMed ID: 33340905
[TBL] [Abstract][Full Text] [Related]
35. Phase II study of pazopanib with oral topotecan in patients with metastatic and non-resectable soft tissue and bone sarcomas.
Schulte B; Mohindra N; Milhem M; Attia S; Robinson S; Monga V; Hirbe AC; Oppelt P; Charlson J; Helenowski I; Abbinanti S; Cehic R; Okuno S; Van Tine BA; Agulnik M
Br J Cancer; 2021 Aug; 125(4):528-533. PubMed ID: 34050255
[TBL] [Abstract][Full Text] [Related]
36. Incidence of pneumothorax in advanced and/or metastatic soft tissue sarcoma patients during pazopanib treatment.
Nakano K; Inagaki L; Tomomatsu J; Motoi N; Gokita T; Ae K; Tanizawa T; Shimoji T; Matsumoto S; Takahashi S
Clin Oncol (R Coll Radiol); 2014 Jun; 26(6):357. PubMed ID: 24630810
[No Abstract] [Full Text] [Related]
37. A retrospective chart review of drug treatment patterns and clinical outcomes among patients with metastatic or recurrent soft tissue sarcoma refractory to one or more prior chemotherapy treatments.
Wagner MJ; Amodu LI; Duh MS; Korves C; Solleza F; Manson SC; Diaz J; Neary MP; Demetri GD
BMC Cancer; 2015 Mar; 15():175. PubMed ID: 25885530
[TBL] [Abstract][Full Text] [Related]
38. [First Hungarian experience with pazopanib therapy for patients with metastatic renal cancer].
Maráz A; Bodrogi I; Csejtei A; Dank M; Géczi L; Küronya Z; Mangel L; Petrányi A; Szûcs M; Bodoky G
Magy Onkol; 2013 Sep; 57(3):173-6. PubMed ID: 24107823
[TBL] [Abstract][Full Text] [Related]
39. Follow-up after primary treatment of soft tissue sarcoma of extremities: impact of frequency of follow-up imaging on disease-specific survival.
Chou YS; Liu CY; Chen WM; Chen TH; Chen PC; Wu HT; Chiou HJ; Shiau CY; Wu YC; Liu CL; Chao TC; Tzeng CH; Yen CC
J Surg Oncol; 2012 Aug; 106(2):155-61. PubMed ID: 22297812
[TBL] [Abstract][Full Text] [Related]
40. The real-life outcome of pazopanib in patients with advanced soft tissue sarcoma: A retrospective cross-sectional study of a Turkish cohort.
Karaağaç M; Sezgin Y; Eryılmaz MK; Araz M; Kaplan MA; Artaç M
J Oncol Pharm Pract; 2020 Oct; 26(7):1657-1666. PubMed ID: 32063110
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]